[HTML][HTML] The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors
M Wang, X Zhai, J Li, J Guan, S Xu, YY Li… - Frontiers in …, 2021 - frontiersin.org
Recently, the overall survival (OS) and progression-free survival (PFS) of patients with
advanced cancer has been significantly improved due to the application of immune …
advanced cancer has been significantly improved due to the application of immune …
[HTML][HTML] C-reactive protein: a target for therapy to reduce inflammation
SA Rizo-Téllez, M Sekheri, JG Filep - Frontiers in immunology, 2023 - frontiersin.org
C-reactive protein (CRP) is well-recognized as a sensitive biomarker of inflammation.
Association of elevations in plasma/serum CRP level with disease state has received …
Association of elevations in plasma/serum CRP level with disease state has received …
[HTML][HTML] C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer
Biomarkers for predicting response to anti-programmed death-1 (PD-1) immune checkpoint
blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor …
blockade (ICB) in non-small cell lung cancer (NSCLC) remain in demand. Since anti-tumor …
[HTML][HTML] Combined C-reactive protein and novel inflammatory parameters as a predictor in cancer—what can we learn from the hematological experience?
Ø Bruserud, HH Aarstad, THA Tvedt - Cancers, 2020 - mdpi.com
The acute phase reaction is a systemic response to acute or chronic inflammation. The
serum level of C-reactive protein (CRP) is the only acute phase biomarker widely used in …
serum level of C-reactive protein (CRP) is the only acute phase biomarker widely used in …
[HTML][HTML] Immunopathogenesis of immune checkpoint inhibitor-related adverse events: roles of the intestinal microbiome and Th17 cells
R Anderson, AJ Theron, BL Rapoport - Frontiers in immunology, 2019 - frontiersin.org
The advent of novel, innovative, and effective anti-cancer immunotherapies has engendered
an era of renewed optimism among cancer specialists and their patients. Foremost among …
an era of renewed optimism among cancer specialists and their patients. Foremost among …
[HTML][HTML] Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab
S Fukuda, K Saito, Y Yasuda, T Kijima… - … for Immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background The dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a
prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor …
prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor …
[HTML][HTML] Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures
F Wei, K Azuma, Y Nakahara, H Saito… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitor (ICI) therapy has substantially improved the overall
survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response …
survival (OS) in patients with non-small-cell lung cancer (NSCLC); however, its response …
[HTML][HTML] Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity
IS Chin, A Khan, A Olsson-Brown, S Papa… - NPJ Genomic …, 2022 - nature.com
Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of various cancer
types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting …
types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting …
[HTML][HTML] Development of an immune-related risk signature for predicting prognosis in lung squamous cell carcinoma
D Fu, B Zhang, L Yang, S Huang, W Xin - Frontiers in Genetics, 2020 - frontiersin.org
Lung squamous cell carcinoma (LSCC) is the most common subtype of non-small cell lung
cancer. Immunotherapy has become an effective treatment in recent years, while patients …
cancer. Immunotherapy has become an effective treatment in recent years, while patients …
Phase I and biomarker study of the Wnt pathway modulator DKN-01 in combination with gemcitabine/cisplatin in advanced biliary tract cancer
L Goyal, C Sirard, M Schrag, MH Kagey, JR Eads… - Clinical Cancer …, 2020 - AACR
Abstract Purpose: Dickkopf-1 (DKK1) modulates Wnt signaling, promoting tumor growth,
metastasis, and immunosuppression. High DKK1 expression has been detected in various …
metastasis, and immunosuppression. High DKK1 expression has been detected in various …